These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37691291)

  • 1. The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?
    Boutari C; Athyros VG
    Angiology; 2024 Mar; 75(3):205-207. PubMed ID: 37691291
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations.
    Lu X; Yang R; Chen Y; Chen D
    Clin Mol Hepatol; 2024 Jul; 30(3):582-584. PubMed ID: 38163440
    [No Abstract]   [Full Text] [Related]  

  • 3. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.
    Polyzos SA; Mantzoros CS
    Metabolism; 2024 Aug; 157():155936. PubMed ID: 38763229
    [No Abstract]   [Full Text] [Related]  

  • 5. Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella.
    Noureddin M; Wei L; Castera L; Tsochatzis EA
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):9-11. PubMed ID: 37848118
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
    Rinella ME; Castro Narro GE; Krag A; Terrault N; Newsome PN
    J Hepatol; 2024 Jul; 81(1):e20-e21. PubMed ID: 38906627
    [No Abstract]   [Full Text] [Related]  

  • 7. In response to: Steatotic liver disease-know your enemies.
    Le MH; Henry L; Nguyen MH
    Clin Mol Hepatol; 2024 Apr; 30(2):284-286. PubMed ID: 38373421
    [No Abstract]   [Full Text] [Related]  

  • 8. [Not Available].
    Hansen CD; Lindvig KP; Grønbæk H; Gluud LL; Thiele M; Krag A
    Ugeskr Laeger; 2024 May; 186(19):. PubMed ID: 38808766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.
    Han AL
    BMC Endocr Disord; 2021 May; 21(1):91. PubMed ID: 33933056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.
    Duell PB; Welty FK; Miller M; Chait A; Hammond G; Ahmad Z; Cohen DE; Horton JD; Pressman GS; Toth PP;
    Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e168-e185. PubMed ID: 35418240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Risk in Children with Nonalcoholic Fatty Liver Disease (NAFLD).
    Chociej AB; Wasilewska N; Flisiak-Jackiewicz M; Lebensztejn D
    Curr Pediatr Rev; 2020; 16(4):294-297. PubMed ID: 33038914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
    Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
    Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease.
    Tsutsumi T; Nakano D; Kawaguchi M; Takahashi H; Kawaguchi T
    Clin Mol Hepatol; 2024 Apr; 30(2):266-268. PubMed ID: 38471499
    [No Abstract]   [Full Text] [Related]  

  • 14. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.
    Konishi K; Miyake T; Furukawa S; Senba H; Kanzaki S; Nakaguchi H; Yukimoto A; Nakamura Y; Watanabe T; Koizumi Y; Yoshida O; Tokumoto Y; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
    Atherosclerosis; 2020 Apr; 299():32-37. PubMed ID: 32203743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    Choudhary NS; Dhampalwar S; Saraf N; Soin AS
    J Hepatol; 2024 Feb; 80(2):e77-e79. PubMed ID: 37717602
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19.
    Ji D; Zhang M; Qin E; Zhang L; Xu J; Wang Y; Cheng G; Wang F; Lau G
    Metabolism; 2021 Feb; 115():154437. PubMed ID: 33220249
    [No Abstract]   [Full Text] [Related]  

  • 17. Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population.
    Oh JH; Jun DW
    Gut Liver; 2024 Mar; 18(2):197-198. PubMed ID: 38481277
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
    Kim HS; Cho YK
    Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
    Kim GA; Moon JH; Kim W
    Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base.
    Mahawar KK; Parmar C; Graham Y; Abouleid A; Carr WR; Jennings N; Schroeder N; Small PK
    Obes Surg; 2016 Jan; 26(1):177-81. PubMed ID: 26428254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.